Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

GFT505 Reduces the Risk of Cardiovascular Events

Published: Friday, May 17, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Treatment with GFT505 significantly reduces the level of “remnant cholesterol”.

GENFIT has announced that GFT505 reduces a new component of cardiovascular risk: the cholesterol contained in lipid particles other than LDL and HDL, also known as ‘remnant cholesterol’.

All the Phase II clinical studies performed to date have shown that GFT505 improves classical lipid risk factors. It lowers the level of LDL-cholesterol (‘bad cholesterol’), increases the level of HDL-cholesterol (“good cholesterol”), and lowers the level of non-HDL-cholesterol and triglycerides in the blood.

A recently published study (Varbo et al. J Am Coll Cardiol 2013; 61: 427-36) of more than 70,000 subjects shows that the level of cholesterol not contained in LDL or HDL particles, also known as ‘remnant cholesterol’, is directly and causally associated with an elevated risk of ischemic heart disease.

According to this study, subjects with increased levels of remnant cholesterol have a two- to three-fold greater risk of developing ischemic heart disease than subjects with low levels of remnant cholesterol.

The data from the Phase IIa studies, GFT505-209-4 in pre-diabetic patients and GFT505-210-5 in diabetic patients, have been analyzed.

This analysis demonstrates that treatment with GFT505 (80 mg/day) significantly reduces the level of “remnant cholesterol” in these two patient populations.

In the GFT505-209-4 study, the effect of GFT505 on measured remnant cholesterol was -24% (p=0.0046) compared to the placebo group after 28 days of treatment.

Consistently, after 3 months of treatment in diabetic patients (study GFT505-210-5), the effect of GFT505 on calculated remnant cholesterol compared to the placebo group was -46% (p=0.01).

Two experts commented these results.
Professor Gerald Watts (University of Western Australia) declared: “GFT505, when administered as monotherapy to patients with pre-diabetes or diabetes, leads to a significant fall in plasma triglyceride and triglyceride-rich lipoprotein remnants. The 10-15% reduction in non-HDL cholesterol could be clinically significant in terms of a proportional reduction in cardiovascular events in patients with the metabolic syndrome.”

Professor Bart Staels, University of Lille 2 and President of the Scientific Advisory Board, precised: “NAFLD/NASH is considered to be the hepatic complication of the metabolic syndrome. Overall, the results of large outcome trials show that statin treatment decreases the cardiovascular risk by only 30%, the remaining 70% representing a high residual cardiovascular risk. Given Varbo et al’s demonstration of the causal link between the level of remnant cholesterol and cardiovascular risk, the beneficial effects of GFT505 on remnant cholesterol further strengthen its cardioprotective profile.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genfit Announces Positive Results From Proprietary Nash Biomarker Program
The company has designed a diagnostic tool – as an alternative to invasive liver biopsy – to identify NASH patients that deserve to be treated, according to the consensual definition agreed between experts and regulatory agencies.
Tuesday, September 22, 2015
FDA Grants Fast Track Designation to GENFIT's GFT505 in NASH
The aim is to ensure that new therapies for serious conditions are approved and available to patients as soon as possible.
Tuesday, February 18, 2014
GENFIT: The FDA Grants Fast Track Designation to GFT505 in NASH
Granting accelerate the development of GFT505 and reduce the time to market.
Tuesday, February 18, 2014
Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
Genfit has announced that it has achieved a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.
Thursday, May 06, 2010
GENFIT Assembles Four International Experts for it's Scientific Advisory Board
GENFIT, a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announces a new Scientific Advisory Board consisting of internationally renowned experts.
Thursday, October 30, 2008
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos